Expanding Portfolio

Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis

Colin Kerr

Published: Friday, February 1, 2019

Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis. The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials. Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.” www.oculis.com

Latest Articles

Thinking Beyond Optics: Diversity, Equity, and Inclusion (DEI) and Unconscious Bias in Ophthalmology

Beyond Sight: A Clearer Vision for Equity in Ophthalmology

Refractions of Bias: Seeing DEI Clearly in Ophthalmology

Happy Patients, Higher Volumes

Digitalisation reduces errors and saves time, making a surgeon’s life easier.

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.